logo-loader
viewZelira Therapeutics Ltd

Zelira Therapeutics overseas interest boosts capital raising

Oversubscriptions from overseas investors boost the amount raised in the placement to total $4.64 million.

Zelira Therapeutics Ltd. - Zelira Therapeutics overseas interest boosts capital raising
Shares under the placement have an issue price of 5 cents

Zelira Therapeutics Ltd (ASX:ZLD) (OTCQB:ZLDAF) has accepted applications from overseas investors for an additional 1.08 million shares as part of the share placement.

Following the acceptance of oversubscriptions, the placement will raise $4.64 million in total.

The funds will be used to accelerate Zelira’s plans to launch multiple products into global markets in 2020 and to advance its clinical programs, including its Insomnia and Opioid Sparing trials, which are due to read-out in the first half of this year.

A global therapeutic medicinal cannabis company

Zelira is a leading global therapeutic medicinal cannabis company with access to the world’s largest and fastest-growing cannabis markets.

The company owns a portfolio of proprietary revenue-generating products and a pipeline of candidates undergoing clinical development that are positioned to enter global markets from 2020.

It is currently undertaking:

  • Human clinical trial programs focused on insomnia, autism and opioid reduction with activities in Australia and the US; and
  • Pre-clinical research examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.

Quick facts: Zelira Therapeutics Ltd

Price: 0.032 AUD

ASX:ZLD
Market: ASX
Market Cap: $30.92 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Zelira Therapeutics releases interim data for Phase II...

Zelira Therapeutics Ltd (ASX:ZLD) managing director Dr Richard Hopkins, chairman Osagie Imasogie and clinical trial principal investigator Professor Peter Eastwood, of the University of Western Australia, update Proactive on results from the company’s Phase II clinical trial of medicinal...

on 02/21/2020

2 min read